Ionis Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Ionis Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2019-03-31 | 2018-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-06-30 | 2006-03-31 | 2005-09-30 | 2005-06-30 | 2005-03-31 | 2004-09-30 | 2004-06-30 | 2004-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| commercial revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| product sales | 19,273,000 | 6,287,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| royalty revenue | 69,952,000 | 64,166,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other commercial revenue | 13,531,000 | 5,715,000 | 12,103,000 | 13,152,000 | 11,512,000 | 20,013,000 | 16,977,000 | 16,828,000 | 16,885,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| total commercial revenue | 102,756,000 | 76,168,000 | 85,716,000 | 75,731,000 | 72,036,000 | 59,593,000 | 78,845,000 | 84,081,000 | 77,897,000 | 67,768,000 | 80,479,000 | 72,410,000 | 78,184,000 | 72,285,000 | 68,088,000 | |||||||||||||||||||||||||||||||||||||||||
| research and development revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| collaborative agreement revenue | 336,921,000 | 45,031,000 | 96,894,000 | 44,883,000 | 141,524,000 | 49,345,000 | 179,144,000 | 44,167,000 | 91,013,000 | 38,334,000 | 49,940,000 | 69,250,000 | 38,247,000 | 49,784,000 | ||||||||||||||||||||||||||||||||||||||||||
| wainua joint development revenue | 12,372,000 | 10,413,000 | 43,966,000 | 13,200,000 | 11,690,000 | 10,559,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| total research and development revenue | 349,293,000 | 55,444,000 | 140,860,000 | 58,083,000 | 153,214,000 | 59,904,000 | 245,660,000 | 60,126,000 | 110,514,000 | 62,756,000 | 71,410,000 | 87,357,000 | 55,607,000 | 69,634,000 | ||||||||||||||||||||||||||||||||||||||||||
| total revenue | 452,049,000 | 131,612,000 | 226,576,000 | 133,814,000 | 225,250,000 | 119,497,000 | 324,505,000 | 144,207,000 | 188,411,000 | 130,524,000 | 151,889,000 | 159,767,000 | 133,791,000 | 141,919,000 | 297,214,000 | 32,325,000 | 44,063,000 | 57,076,000 | 28,161,000 | 42,249,000 | 23,585,000 | 38,092,000 | 43,360,000 | 19,873,000 | 11,601,000 | 47,340,000 | 23,235,000 | 32,403,000 | 20,713,000 | 24,823,000 | 21,147,000 | 26,420,000 | 28,624,000 | 23,503,000 | 29,926,000 | 32,262,000 | 26,771,000 | 30,992,000 | 31,576,000 | 20,661,000 | 32,215,000 | 32,961,000 | 21,354,000 | 38,631,000 | 3,813,000 | 2,450,000 | 11,945,000 | 3,253,000 | 4,375,000 | 4,958,000 | 7,458,000 | 105,929,843,000 | 7,442,000 | 9,093,000 | 9,843,000 | 12,303,000 |
| yoy | 100.69% | 10.14% | -30.18% | -7.21% | 19.55% | -8.45% | 113.65% | -9.74% | 40.82% | -8.03% | -48.90% | 394.25% | 203.64% | 148.65% | 955.41% | -23.49% | 86.83% | 49.84% | -35.05% | 112.59% | 103.30% | -19.54% | 86.62% | -38.67% | -43.99% | 90.71% | 9.87% | 22.65% | -27.64% | 5.62% | -29.34% | -18.11% | 6.92% | -24.16% | -5.23% | 56.15% | -16.90% | -5.97% | 47.87% | -46.52% | 744.87% | 1245.35% | 78.77% | 1087.55% | -12.85% | -50.58% | 60.16% | -100.00% | -41.21% | -45.47% | -24.23% | 860908.23% | ||||
| qoq | 243.47% | -41.91% | 69.32% | -40.59% | 88.50% | -63.18% | 125.03% | -23.46% | 44.35% | -14.07% | -4.93% | 19.42% | -5.73% | -52.25% | 819.46% | -26.64% | -22.80% | 102.68% | -33.35% | 79.14% | -38.08% | -12.15% | 118.19% | 71.30% | -75.49% | 103.74% | -28.29% | 56.44% | -16.56% | 17.38% | -19.96% | -7.70% | 21.79% | -21.46% | -7.24% | 20.51% | -13.62% | -1.85% | 52.83% | -35.87% | -2.26% | 54.36% | -44.72% | 913.14% | 55.63% | -79.49% | 267.20% | -25.65% | -11.76% | -33.52% | -99.99% | 1423305.58% | -18.16% | -7.62% | -20.00% | |
| expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of sales | 4,151,000 | 1,463,000 | 3,830,000 | 1,071,000 | 4,164,000 | 2,151,000 | 3,062,000 | 2,191,000 | 2,537,000 | 1,343,000 | 3,686,000 | 1,515,000 | 4,745,000 | 4,170,000 | ||||||||||||||||||||||||||||||||||||||||||
| gross profit | 447,898,000 | 130,149,000 | 222,746,000 | 132,743,000 | 221,086,000 | 117,346,000 | 321,443,000 | 142,016,000 | 185,874,000 | 129,181,000 | 148,203,000 | 158,252,000 | 129,046,000 | 137,749,000 | ||||||||||||||||||||||||||||||||||||||||||
| yoy | 102.59% | 10.91% | -30.70% | -6.53% | 18.94% | -9.16% | 116.89% | -10.26% | 44.04% | -6.22% | ||||||||||||||||||||||||||||||||||||||||||||||
| qoq | 244.14% | -41.57% | 67.80% | -39.96% | 88.41% | -63.49% | 126.34% | -23.60% | 43.89% | -12.84% | -6.35% | 22.63% | -6.32% | |||||||||||||||||||||||||||||||||||||||||||
| gross margin % | 99.08% | 98.89% | 98.31% | 99.20% | 98.15% | 98.20% | 99.06% | 98.48% | 98.65% | 98.97% | 97.57% | 99.05% | 96.45% | 97.06% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| research, development and patent | 217,460,000 | 200,759,000 | 245,490,000 | 219,761,000 | 222,064,000 | 214,215,000 | 256,555,000 | 215,330,000 | 229,927,000 | 197,813,000 | 308,272,000 | 182,990,000 | 180,758,000 | 161,126,000 | 106,417,000 | |||||||||||||||||||||||||||||||||||||||||
| selling, general and administrative | 90,622,000 | 76,250,000 | 88,079,000 | 61,638,000 | 65,113,000 | 52,644,000 | 71,011,000 | 69,951,000 | 46,142,000 | 45,516,000 | 47,950,000 | 34,416,000 | 33,802,000 | 34,127,000 | 68,221,000 | 3,301,500 | 4,571,000 | 4,899,000 | 3,736,000 | 4,278,000 | 3,089,000 | 3,402,000 | 4,520,000 | 2,823,000 | ||||||||||||||||||||||||||||||||
| total operating expenses | 312,233,000 | 278,472,000 | 337,399,000 | 282,470,000 | 291,341,000 | 269,010,000 | 330,628,000 | 287,472,000 | 278,606,000 | 244,672,000 | 359,908,000 | 218,921,000 | 219,305,000 | 199,423,000 | 175,679,000 | 46,777,750 | 65,556,000 | 63,726,000 | 57,828,000 | 62,107,000 | 49,090,000 | 46,020,000 | 41,735,000 | 45,992,000 | 39,647,000 | 43,644,000 | 41,690,000 | 51,019,000 | 43,029,000 | 38,883,000 | 37,255,000 | 42,278,000 | 37,571,000 | 42,175,000 | 34,806,000 | 43,933,000 | 37,167,000 | 35,819,000 | 32,218,000 | 17,433,000 | 36,539,000 | 36,094,000 | 30,185,000 | 28,574,000 | 23,473,000 | 23,351,000 | 28,681,000 | 21,517,000 | 21,477,000 | 20,974,000 | 19,602,000 | 2,351,531,183,000 | 30,949,000 | 31,473,000 | 31,183,000 | 34,638,000 |
| income from operations | 139,816,000 | -146,860,000 | -110,823,000 | -148,656,000 | -66,091,000 | -149,513,000 | -6,123,000 | -143,265,000 | -90,195,000 | -114,148,000 | -208,019,000 | -59,154,000 | -85,514,000 | -57,504,000 | 121,535,000 | -14,452,750 | -21,493,000 | -6,650,000 | -29,667,000 | 1,625,000 | 3,696,000 | 10,057,000 | ||||||||||||||||||||||||||||||||||
| yoy | -311.55% | -1.77% | 1709.95% | 3.76% | -26.72% | 30.98% | -97.06% | 142.19% | 5.47% | 98.50% | -271.16% | 309.29% | 297.87% | 764.72% | -509.66% | -1925.66% | ||||||||||||||||||||||||||||||||||||||||
| qoq | -195.20% | 32.52% | -25.45% | 124.93% | -55.80% | 2341.83% | -95.73% | 58.84% | -20.98% | -45.13% | 251.66% | -30.83% | 48.71% | -147.31% | -940.91% | -32.76% | 223.20% | -77.58% | ||||||||||||||||||||||||||||||||||||||
| operating margin % | 30.93% | -111.59% | -48.91% | -111.09% | -29.34% | -125.12% | -1.89% | -99.35% | -47.87% | -87.45% | -136.95% | -37.03% | -63.92% | -40.52% | 40.89% | -44.71% | -48.78% | -11.65% | -105.35% | 0% | 3.75% | 0% | 7.81% | 0% | 0% | 0% | 0% | 26.03% | 0% | |||||||||||||||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| investment income | 24,687,000 | 24,667,000 | 28,910,000 | 26,228,000 | 25,599,000 | 26,285,000 | 25,686,000 | 23,935,000 | 20,792,000 | 18,627,000 | 11,884,000 | 7,524,000 | 3,403,000 | 1,993,000 | 12,142,000 | 500,750 | 675,000 | 671,000 | 657,000 | 685,000 | 434,000 | 589,000 | 376,000 | 359,000 | 408,000 | 477,000 | 600,000 | 518,000 | 575,000 | 616,000 | 705,000 | 780,000 | 776,000 | 859,000 | 955,000 | 1,118,000 | 1,430,000 | 1,678,000 | 2,192,000 | -1,743,000 | 7,546,000 | 560,000 | 4,956,000 | 2,603,000 | 3,053,000 | 3,401,000 | 2,123,000 | 1,682,000 | 1,344,000 | 811,000 | 1,241,000 | 349,842,000 | 504,000 | 561,000 | 842,000 | 1,133,000 |
| interest expense | -4,108,000 | -4,191,000 | -4,161,000 | -4,490,000 | -4,151,000 | -4,558,000 | -4,203,000 | -2,291,000 | -1,608,000 | -1,731,000 | -2,139,000 | -2,130,000 | -2,122,000 | -11,599,000 | -3,725,500 | -4,998,000 | -4,961,000 | -4,943,000 | ||||||||||||||||||||||||||||||||||||||
| interest expense related to sale of future royalties | -18,822,000 | -18,669,000 | -18,533,000 | -18,296,000 | -17,959,000 | -17,849,000 | -17,779,000 | -17,655,000 | -15,515,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| loss on investments | -529,000 | -6,625,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income | 102,000 | 465,000 | 314,000 | 142,000 | 610,000 | 277,000 | 399,000 | 2,447,000 | 11,183,000 | 230,000 | -1,980,750 | 4,713,000 | -12,297,000 | 187,000 | ||||||||||||||||||||||||||||||||||||||||||
| income before income tax benefit | 123,531,000 | -107,039,000 | -144,101,000 | -44,330,000 | -46,709,000 | -17,508,750 | -25,278,000 | -33,556,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| income tax benefit | 20,000 | 2,690,000 | 3,621,000 | -8,100,000 | -283,000 | -500 | -1,398,000 | -881,000 | 2,276,000 | -523,000 | 5,193,000 | 1,181,000 | 64,000 | 8,405,000 | 706,000 | 1,156,250 | 3,968,000 | 717,000 | ||||||||||||||||||||||||||||||||||||||
| net income | 123,551,000 | -146,938,000 | -104,349,000 | -140,480,000 | -66,265,000 | -142,803,000 | -9,263,000 | -147,410,000 | -85,290,000 | -124,323,000 | -52,430,000 | -46,992,000 | -105,135,000 | -65,165,000 | 90,884,000 | -17,509,250 | -26,676,000 | -12,081,000 | -31,280,000 | -24,276,000 | -24,570,000 | -10,126,000 | -1,672,000 | -2,637,000 | -37,639,000 | -1,207,000 | -23,995,000 | -16,191,250 | -26,882,000 | -17,889,000 | -19,994,000 | -8,445,000 | 170,930,000 | 3,188,000 | 20,007,000 | |||||||||||||||||||||
| yoy | -286.45% | 2.90% | 1026.51% | -4.70% | -22.31% | 14.86% | -82.33% | 213.69% | -18.88% | 90.78% | -157.69% | 168.38% | 294.12% | 439.40% | -390.55% | -27.87% | 8.57% | 19.31% | 1770.81% | 820.59% | -34.72% | 738.94% | -93.03% | -83.71% | 40.02% | -93.25% | 20.01% | |||||||||||||||||||||||||||||
| qoq | -184.08% | 40.81% | -25.72% | 112.00% | -53.60% | 1441.65% | -93.72% | 72.83% | -31.40% | 137.12% | 11.57% | -55.30% | 61.34% | -171.70% | -619.06% | -34.36% | 120.81% | -61.38% | 28.85% | -1.20% | 142.64% | 505.62% | -36.59% | -92.99% | 3018.39% | -94.97% | 48.20% | -39.77% | 50.27% | -10.53% | ||||||||||||||||||||||||||
| net income margin % | 27.33% | -111.64% | -46.05% | -104.98% | -29.42% | -119.50% | -2.85% | -102.22% | -45.27% | -95.25% | -34.52% | -29.41% | -78.58% | -45.92% | 30.58% | -54.17% | -60.54% | -21.17% | -111.08% | -57.46% | -104.18% | -26.58% | -3.86% | -13.27% | -324.45% | -2.55% | -103.27% | -49.97% | -129.78% | -72.07% | -94.55% | 0% | -26.18% | 541.33% | 0% | 9.90% | 0% | 0% | 51.79% | 0% | 0% | 0% | 0% | 0% | 0% | |||||||||||
| basic net income per share | 0.78 | 0.63 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted net income per share | 0.7 | 0.62 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| shares used in computing basic net income per share | 159,137 | 138,582 | 24,497 | 98,320 | 98,116 | 97,521 | 23,446.5 | 95,863 | ||||||||||||||||||||||||||||||||||||||||||||||||
| shares used in computing diluted net income per share | 182,331 | 141,537 | 24,497 | 98,320 | 98,116 | 111,274 | 23,446.5 | 100,181 | ||||||||||||||||||||||||||||||||||||||||||||||||
| gain on investments | -2,164,000 | -80,250 | 879,000 | -3,533,000 | 2,333,000 | -161,000 | -1,943,000 | 718,000 | 3,283,000 | 2,347,000 | -6,337,000 | 168,750 | 538,000 | -260,000 | 397,000 | 305,000 | 175,000 | 840,000 | 1,058,000 | 1,446,000 | 2,000 | 17,000 | 18,000 | 34,000 | -710,000 | 123,000 | 2,612,000 | 1,989,000 | 1,521,000 | 2,263,000 | ||||||||||||||||||||||||||
| income before income tax expense | -146,822,000 | -66,201,000 | -142,728,000 | -82,799,500 | -140,808,000 | -77,448,000 | -112,943,000 | -102,875,000 | -64,071,000 | 121,931,000 | -11,200,000 | |||||||||||||||||||||||||||||||||||||||||||||
| income tax expense | -116,000 | -64,000 | -75,000 | -6,456,250 | -6,602,000 | -7,842,000 | -11,380,000 | -2,260,000 | -1,094,000 | -31,047,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per share | -0.93 | -0.66 | -0.95 | -0.45 | -0.98 | -0.06 | -1.03 | -0.6 | -0.87 | -0.37 | -0.33 | -0.74 | -0.46 | -0.15 | -0.23 | -0.1 | -0.27 | -0.22 | -0.21 | -0.09 | -0.02 | -0.02 | -0.37 | -0.01 | -0.24 | -0.163 | -0.27 | -0.18 | -0.01 | 0.03 | -0.02 | -0.05 | -1.25 | -0.13 | -0.16 | -0.18 | -0.16 | -0.03 | -0.24 | -0.24 | -0.52 | -0.57 | -0.47 | -0.47 | ||||||||||||
| shares used in computing basic and diluted net income per share | 158,735 | 2,811 | 148,593 | 145,958 | 145,538 | 138 | 143,317 | 143,098 | 142,735 | 66 | 141,950 | 141,794 | 141,599 | 29,377.75 | 117,811 | 117,588 | 117,128 | 1,894 | 115,263 | 108,539 | 101,875 | 225 | 100,680 | 100,213 | 100,157 | 36 | 99,687 | 99,602 | 99,569 | 42 | 99,196 | 99,091 | 99,013 | 94,675 | 90,799 | 83,942 | 82,548 | 82,456 | 1,374 | 73,588 | 72,822 | 72,377 | 64,086 | 5,752,456,111 | 57,521 | 57,267 | 56,111 | 55,858 | ||||||||
| spinraza royalties | 63,684,000 | 57,208,000 | 56,743,000 | 38,455,000 | 61,868,000 | 67,253,000 | 61,012,000 | 50,247,000 | 67,222,000 | 61,647,000 | 59,627,000 | 53,818,000 | 59,711,000 | |||||||||||||||||||||||||||||||||||||||||||
| wainua royalties | 9,929,000 | 5,371,000 | 3,781,000 | 1,125,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| eplontersen joint development revenue | 14,970,750 | 15,959,000 | 19,501,000 | 24,422,000 | 21,470,000 | 18,107,000 | 17,360,000 | 19,850,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| tegsedi and waylivra revenue | 6,478,000 | 7,584,000 | 5,920,000 | 10,386,000 | 6,160,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| licensing and other royalty revenue | 11,043,000 | 5,673,000 | 4,843,000 | 8,171,000 | 12,307,000 | 1,623,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| tegsedi product sales | 6,754,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development revenue under collaborative agreements | 229,126,000 | 29,993,750 | 43,798,000 | 56,628,000 | 19,550,000 | 41,276,000 | 23,383,000 | 37,615,000 | 41,921,000 | 19,015,000 | 11,127,000 | 47,140,000 | 21,818,000 | 31,682,000 | 20,189,000 | 24,305,000 | 20,014,000 | 25,437,000 | 27,785,000 | 21,143,000 | 28,556,000 | 21,716,000 | 25,962,000 | 30,768,000 | 29,685,000 | 20,114,000 | 31,240,000 | 26,814,000 | 20,686,000 | 11,921,000 | 3,482,000 | 2,002,000 | 3,831,000 | 2,469,000 | 4,322,000 | 4,468,000 | 7,122,000 | 104,388,217,000 | 7,135,000 | 9,055,000 | 8,217,000 | 6,998,000 | ||||||||||||||
| cost of products sold | 1,041,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other incomes | -147,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net (income) loss attributable to noncontrolling interest in akcea therapeutics, inc. | -6,441,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to ionis pharmaceuticals, inc. common stockholders | 84,443,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| licensing and royalty revenue | 2,331,250 | 265,000 | 448,000 | 8,611,000 | 973,000 | 202,000 | 477,000 | 1,439,000 | 858,000 | 474,000 | 200,000 | 1,417,000 | 721,000 | 524,000 | 518,000 | 1,133,000 | 983,000 | 839,000 | 2,360,000 | 1,370,000 | 10,546,000 | 809,000 | 224,000 | 1,891,000 | 547,000 | 975,000 | 6,147,000 | 668,000 | 26,710,000 | 331,000 | 448,000 | 8,114,000 | 784,000 | 53,000 | 490,000 | 336,000 | 1,541,626,000 | 307,000 | 38,000 | 1,626,000 | 5,305,000 | |||||||||||||||
| research, development and patent expenses | 240,802,000 | 61,086,000 | 59,264,000 | 53,448,000 | 57,430,000 | 45,660,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 3,328,250 | 4,470,000 | 4,462,000 | 4,380,000 | 4,677,000 | 3,430,000 | 3,389,000 | 3,423,000 | 3,234,000 | 3,096,000 | 3,209,000 | 2,976,000 | 3,800,000 | 3,105,000 | 2,874,000 | 3,010,000 | 2,945,000 | 2,855,000 | 3,051,000 | 2,819,000 | 3,830,000 | 3,335,000 | 3,673,000 | 3,677,000 | 2,710,000 | 2,566,000 | 1,724,000 | 19,102,568,000 | 2,137,000 | 2,373,000 | 2,568,000 | 2,453,000 | ||||||||||||||||||||||||
| equity in net income of regulus therapeutics inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on early retirement of debt | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 42,631,000 | 38,312,000 | 42,758,000 | 36,551,000 | 40,435,000 | 38,714,000 | 47,219,000 | 39,924,000 | 36,009,000 | 34,245,000 | 39,333,000 | 34,716,000 | 39,124,000 | 31,987,000 | 40,103,000 | 33,832,000 | 32,146,000 | 28,541,000 | 16,828,000 | 31,968,000 | 31,195,000 | 26,449,000 | 24,296,000 | 20,384,000 | 19,949,000 | 24,240,000 | 18,973,000 | 18,982,000 | 18,372,000 | 18,212,000 | 2,095,032,036,000 | 22,361,000 | 29,566,000 | 32,036,000 | 28,947,000 | |||||||||||||||||||||
| basic and diluted net income | -200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income from continuing operations, before income tax expense | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income from continuing operations | -0.21 | -0.07 | -0.03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| discontinued operations: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income from discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on sale of ibis biosciences, inc., net of tax | 13,884,000 | 171,773,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income from discontinued operations, net of tax | 13,884,000 | 171,744,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to noncontrolling interest in regulus therapeutics inc. | 1,487,000 | 1,136,000 | 857,000 | 913,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income attributable to isis pharmaceuticals, inc. common stockholders | -13,986,000 | -12,454,000 | -25,154,000 | -9,658,000 | -6,958,000 | -6,924,000 | -2,896,000 | 171,843,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income from continuing operations attributable to isis pharmaceuticals, inc. common stockholders | -0.14 | -0.13 | -0.25 | -0.1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income from discontinued operations | 0.14 | 1.76 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income attributable to isis pharmaceuticals, inc. common stockholders | -0.14 | -0.13 | -0.25 | -0.1 | -0.07 | -0.07 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| income from continuing operations, before income tax benefit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income from continuing operations, net of income tax benefit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic net income per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic net income attributable to isis pharmaceuticals, inc. common stockholders | -0.03 | 1.76 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted net income per share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted net income attributable to isis pharmaceuticals, inc. common stockholders | -0.03 | 1.57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss attributed to noncontrolling interest in symphony genisis, inc. | 8,748,000 | 7,603,000 | 6,806,000 | 5,085,250 | 6,733,000 | 13,608,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| loss attributed to noncontrolling interest in regulus therapeutics llc | 764,000 | 1,208,000 | 965,000 | 883,000 | 87,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| loss attributed to noncontrolling interest in ibis biosciences, inc. | 290,750 | 267,000 | 791,000 | 105,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| excess purchase price over carrying value of noncontrolling interest in symphony genisis, inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income applicable to common stock | -8,658,000 | 3,188,000 | -2,208,000 | -4,285,000 | -105,304,000 | -11,024,000 | -13,020,000 | -14,146,000 | -12,105,000 | -2,172,000 | -17,480,000 | -15,172,000 | -29,658,000 | -32,708,000 | -26,129,000 | -26,487,000 | ||||||||||||||||||||||||||||||||||||||||
| restructuring activities | 36,000 | 650,000 | 7,084,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income before noncontrolling interest in symphony genisis, inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| compensation expense/(benefit) related to variable accounting of stock options | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| compensation benefit related to variable accounting of stock options | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| compensation benefit related to stock options | 15,000 | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| accretion of dividends on preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| compensation expense related to stock options | 3,238,000 |
We provide you with 20 years income statements for Ionis Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ionis Pharmaceuticals stock. Explore the full financial landscape of Ionis Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Ionis Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.